Ad is loading...
BZYR
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
CRNX
Price
$54.72
Change
-$4.94 (-8.28%)
Updated
Nov 15 closing price
120 days until earnings call
Ad is loading...

BZYR vs CRNX

Header iconBZYR vs CRNX Comparison
Open Charts BZYR vs CRNXBanner chart's image
Burzynski Research Institute
Price$0.05
Change-$0.00 (-0.00%)
Volume$3K
CapitalizationN/A
Crinetics Pharmaceuticals
Price$54.72
Change-$4.94 (-8.28%)
Volume$908.88K
CapitalizationN/A
BZYR vs CRNX Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
BZYR vs. CRNX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BZYR is a Buy and CRNX is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (BZYR: $0.05 vs. CRNX: $54.72)
Brand notoriety: BZYR and CRNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BZYR: 13% vs. CRNX: 120%
Market capitalization -- BZYR: $6.44M vs. CRNX: $5.07B
BZYR [@Biotechnology] is valued at $6.44M. CRNX’s [@Biotechnology] market capitalization is $5.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BZYR’s FA Score shows that 0 FA rating(s) are green whileCRNX’s FA Score has 1 green FA rating(s).

  • BZYR’s FA Score: 0 green, 5 red.
  • CRNX’s FA Score: 1 green, 4 red.
According to our system of comparison, CRNX is a better buy in the long-term than BZYR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 2 TA indicator(s) are bullish.

  • CRNX’s TA Score: 2 bullish, 7 bearish.

Price Growth

BZYR (@Biotechnology) experienced а +19.49% price change this week, while CRNX (@Biotechnology) price change was -9.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

BZYR is expected to report earnings on Jan 13, 2023.

CRNX is expected to report earnings on Mar 18, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($5.08B) has a higher market cap than BZYR($6.44M). CRNX YTD gains are higher at: 53.794 vs. BZYR (11.341). BZYR has higher annual earnings (EBITDA): -1.54M vs. CRNX (-276.18M). CRNX has more cash in the bank: 863M vs. BZYR (1.22K). CRNX has higher revenues than BZYR: CRNX (1.39M) vs BZYR (0).
BZYRCRNXBZYR / CRNX
Capitalization6.44M5.08B0%
EBITDA-1.54M-276.18M1%
Gain YTD11.34153.79421%
P/E RatioN/AN/A-
Revenue01.39M-
Total Cash1.22K863M0%
Total DebtN/A53.3M-
FUNDAMENTALS RATINGS
BZYR vs CRNX: Fundamental Ratings
BZYR
CRNX
OUTLOOK RATING
1..100
5035
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
1009
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
3744
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (92) in the Pharmaceuticals Major industry is in the same range as BZYR (98) in the null industry. This means that CRNX’s stock grew similarly to BZYR’s over the last 12 months.

CRNX's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is significantly better than the same rating for BZYR (100) in the null industry. This means that CRNX’s stock grew significantly faster than BZYR’s over the last 12 months.

CRNX's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as BZYR (100) in the null industry. This means that CRNX’s stock grew similarly to BZYR’s over the last 12 months.

BZYR's Price Growth Rating (37) in the null industry is in the same range as CRNX (44) in the Pharmaceuticals Major industry. This means that BZYR’s stock grew similarly to CRNX’s over the last 12 months.

BZYR's P/E Growth Rating (100) in the null industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that BZYR’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
78%
MACD
ODDS (%)
Bearish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 6 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
REW10.810.61
+5.98%
ProShares UltraShort Technology
MLPX61.160.52
+0.86%
Global X MLP & Energy Infrastructure ETF
DIVZ33.410.03
+0.09%
Opal Dividend Income ETF
QMAR29.12-0.35
-1.18%
FT Cboe Vest Nasdaq-100 Buffer ETF – Mar
DEMZ35.88-0.61
-1.67%
Democratic Large Cap Core ETF

BZYR and

Correlation & Price change

A.I.dvisor tells us that BZYR and DWTX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BZYR and DWTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BZYR
1D Price
Change %
BZYR100%
N/A
DWTX - BZYR
29%
Poorly correlated
-7.19%
SPRB - BZYR
24%
Poorly correlated
-5.83%
CRNX - BZYR
21%
Poorly correlated
-8.28%
RENB - BZYR
20%
Poorly correlated
-14.60%
BVNRY - BZYR
10%
Poorly correlated
-14.24%
More